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Abstract
Background: Recent studies have shown an association between peripheral arterial disease (PAD) and increased
risk of mortality in hemodialysis (HD) patients; however, the estimates vary widely and are inconsistent. It is
necessary to elucidate the degree of mortality risk for PAD patients in HD population.
Methods: PubMed, EMBASE, Web of Science and Cochrane Library (from inception to September 4th, 2016) were
systematically searched for cohort studies assessing the association between PAD and mortality in HD patients. We
calculated the pooled risk ratios (RRs) with 95% confidence intervals (CI) of all-cause and cardiovascular (CV)
mortality using random effects models. Subgroup analyses were conducted to explore the source of heterogeneity.
Results: The search identified 2,973 potentially eligible records and 10 studies (n = 32,864) were included. Our
meta-analysis revealed that PAD significantly increased the risk of all-cause mortality (RR 2.15, 95 % CI 1.67–2.77,
n = 32,864) and CV mortality (RR 2.99, 95 % CI 1.66-5.38, n = 31,794) in HD patients after multivariate adjustment.
Subgroup analyses showed the study design and follow-up time might be two sources of heterogeneity.
Conclusion: PAD may be a prognostic marker of all-cause and CV mortality in HD patients. More attention should be
paid to diagnosis and management of PAD in HD patients.
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Background
More than 2 million people are suffering from end-stage
renal disease (ESRD) worldwide [1] and growing numbers
of patients are receiving hemodialysis (HD) as a choice for
renal replacement therapy [2]. The mortality of HD patients
was high. A review reported that the annual crude death
rate was in the range of 9.0%–10.2% for dialysis populations
in Japan [2]. Yan et al. [3] followed up 385,074 HD patients
and reported that the one-year mortality was 19.8% and the
five-year mortality was 43.0%. The high mortality of HD
may be due to the plenty of vascular complications, such as
vascular calcification [4] and atherosclerosis [5]. Peripheral
arterial disease (PAD) is a systemic vascular disorder
involving the aorta, iliac, and lower extremity arteries
usually secondary to atherosclerosis [6, 7]. It is diagnosed
by ankle-brachial/arm blood pressure index (ABI, or AAI,
or ABPI) measurement and clinical assessment. ABI is the
ratio of ankle to brachial systolic blood pressure and
patients with an ABI value < 0.9 can be diagnosed as
PAD. The main clinical manifestations of PAD contains
intermittent claudication and critical limb ischemia.
An association between PAD and mortality in HD
patients has been reported since 1916 and the multivariable-
adjusted RRs (95% CI) were 2.9 (1.1–6.7) for all-cause and
7.1 (1.8–33.3) for cardiovascular (CV) mortality [8]. Recent
several studies [9–17] had the consistent outcomes with the
article in 1996 for all-cause mortality. But for CV mortality,
the outcomes were inconsistent. Tsai et al. observed 444
participants with a mean follow-up of 51.5 months and
found that PAD was not significantly associated with CV
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mortality in HD patients [12]. Meanwhile, the estimates of
the associated risk varied widely.
Given the varied and inconsistent results, a meta-
analysis was conducted to summarize the association
between PAD and the risk of all-cause and CV mortality
in patients undergoing HD.
Methods
Our study was designed, conducted, and reported based
on Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) guidelines (Additional file 1)
[18]. Databases (PubMed, EMBASE, Web of Science,
Cochrane Library) were systematically screened to identify
relevant records published up to September 4th, 2016
(Additional file 2) using the following term (Peripheral
artery disease OR Peripheral arterial disease OR PAD
OR Claudication OR limb ischaemia OR limb ischemia OR
ABI OR ABPI OR ankle-brachial index OR Ankle-brachial
blood pressure index OR peripheral arterial occlusive
disease) AND (peritoneal dialysis OR hemodialysis OR
dialysis) AND (Mortality OR Death OR Outcome OR
Prognos*). Besides, we reviewed references of all articles
identified and previous reviews on this topic for additional
further relevant studies. Two authors (Y.Y. and Y.N.)
separately screened titles and abstracts, checked full-text
articles, and determined the final eligible records. If the
eligibility of a record was uncertain, the full text was
reviewed. We resolved divergences by discussion or re-
mitting to a third reviewer, and asked the authors for
help when necessary.
Inclusion criteria
Studies included should meet all of the following criteria:
(1) cohort study, (2) general HD population (i.e., no other
specific diseases, not be given special operation or inter-
ventional therapy), (3) at start, patients with PAD were
recognized using definition of criteria for PAD, and/or
ABI was measured at baseline using a technique stan-
dardized in each study. We considered the patients
with ABI < 0.9 as having PAD, (4) studies had analysis
for association between patients with PAD and the risk
of all-cause and/or CV mortality on follow-up, and
quantitative data evaluating the association was possible
to be extracted, (5) there was no language restriction.
Exclusion criteria
Studies should be excluded by the following criteria: case–
control or cross-sectional studies,animal studies, reviews,
editorials, meeting abstracts, correction, and meta-analyses.
In cases where several publications used the same or
overlapping datasets, we used the study with most thor-
ough information about mortality risk associated with
patients with PAD versus controls.
Data extraction
The following information were extracted by two authors
separately using a uniform prepared data extraction form:
name of first author, publication year, country of origin,
study design, sample size, mean age, proportion of men,
follow-up time, duration of dialysis, prevalence of diabetes
mellitus, prevalence of PAD, diagnosis criterion of PAD,
and events for analysis. We contacted to the original
author in the case of having any doubt. Additional in-
formation was included if response was obtained, other-
wise, we used the available data for our analyses.
Quality assessment
The internal validity (potential bias and methodological
quality) of each study included was appraised by 2
authors independently (Y.Y. and Y.N.) according to
the Newcastle-Ottawa Scale (NOS) [19] for cohort
studies which assessed the following: (1) exposed cohort
truly or somewhat representative, (2) non-exposed cohort
drawn from the same community as the exposed cohort,
(3) ascertainment of exposure, (4) outcome of interest not
present at start, (5A) study controls for age; (5B) study con-
trols for ≥ 3 additional risk factors, (6) assessment of out-
come (independent blind assessment or record linkage), (7)
follow-up ≥ 62 m, (8) complete accounting for cohorts or
subjects lost to follow-up unlikely to introduce bias. This
scale assesses the quality of observational studies and
allocates a maximum of 9 points for quality of study
participants. Overall study quality was graded as good
(score, 7–9), fair (score, 4–6), or poor (score, 0–3) [20].
Divergence was resolved through discussion or consensus.
Statistical analyses
The studies included in our meta-analysis reported dif-
ferent effect measure (hazard ratio [HR] or risk ratio
[RR]), and we combined it as RR throughout this article.
Multivariable-adjusted all-cause and CV mortality data
were expressed as RRs and corresponding 95% CIs.
Random effects models [21] were used to analyze pooled
results of studies in view of high heterogeneity among our
studies. Heterogeneity of RR across included studies was
assessed with Chi-squared based on Q-statistic test (P < 0.1)
and quantified using I2 index. Roughly, Higgins I2 values
were interpreted as low (25%), moderate (50%), and high
(75%) heterogeneity. To explore the source of heterogen-
eity, subgroup analysis and univariable random effects
meta-regression were conducted. Publication bias was
assessed using funnel plots by the Egger regression asym-
metry test. Sensitivity analyses were conducted by recalcu-
lating the pooled RR with removal of one study once. All
analyses were conducted with Stata 10.0 (College Station,
TX, USA). A P value of < 0.05 by 2 tailed was set to be
significant.
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Results
Study selection and study characteristics
We yielded 2,973 potentially relevant records initially
through database searches, and 195 records were remained
eventually for full-text review, of which 186 were excluded.
And 1 additional study was retrieved using hand searching
the reference lists of included studies. Therefore, 10 cohort
studies were included in this meta-analysis [8–17], of which
10 studies were included for meta-analysis of all-cause
mortality [8–17], and 6 were included for CV mortality
[8–10, 12, 15, 16]. Figure 1 showed the summary of
study identification process.
Table 1 showed the characteristics of the 10 included
studies (n = 32,864). They were published from 1996 to
2015. 5 articles were from Asia [9, 13–16], 2 from the
United States [8, 11], 2 from Europe [12, 17], and 1
multinational study from Asia, USA and Europe [10].
An ABI value < 0.9 was the single diagnostic criteria of
PAD in 4 studies [8, 9, 13, 15]. Of the 10 articles included,
8 reported the means duration of dialysis (min: 5.8 years;
max: 19.8 years) [9, 11–13, 15–17]. For the 6 studies (2
were retrospective, and 4 were prospective, n = 31,794) in-
cluded to analyze CVD mortality [8–10, 12, 15, 16], only 1
study did not use ABI < 0.9 to diagnose PAD [10].
According to the NOS, the methodological quality of 9
studies included was graded as good and 1 study was
graded as fair. The details were presented in Table 2.
Primary outcomes
The analysis pooled data for all-cause mortality from 10
studies (weights: 5.37%–15.97%) and CV mortality from
6 studies (weights, 9.68%–23.63%). Both data sets were
heterogeneous (all-cause mortality, I2 = 65.5% and CV
mortality, I2 = 79.7%), therefore, the analyses used random
effects models. Overall, PAD was associated with an in-
creased all-cause mortality after multivariate adjustment
(RR: 2.15, 95% CI 1.67–2.77) (Fig. 2). Meanwhile, PAD
significantly increased CV mortality (RR: 2.99, 95%CI
1.65-5.36) (Fig. 3). The associations remained significant
after omitting any single study conforming to Jackknife
sensitivity analysis (All-cause mortality: Additional file 3
and CV mortality: Additional file 4). There was publica-
tion bias identified by Egger’s test for all-cause mortality
(P = 0.002) (Additional file 5) and CV mortality (P = 0.015)
(Additional file 6).
Subgroup meta-analysis
For all-cause mortality, we further conducted subgroup
meta-analysis. Table 3 showed possible confounding
factors and outcomes. In the subgroups of prospective
study, retrospective study, follow-up time < 62 months,
follow-up time ≥ 62 months, prevalence of diabetes mellitus
(%) < 29, prevalence of PAD (%) ≥ 26, duration of dialy-
sis < 9.4 years, and duration of dialysis ≥ 9.4 years, no
statistical heterogeneity was detected (all P values > 0.1).
Fig. 1 Flow diagram of selection of studies
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Table 1 Characteristics of included studies
Study Country Design Sample size Mean age
(years)






PAD (%) Diagnosis of PAD Events for analysis
Fishbane et al. 1996 [8] USA PC 132 61.5 59 12 NA 25.0 35.0 ABI AC/CV mortality
Ono et al. 2003 [9] Japan PC 1010 60.6 63.5 24 6.5 33.8 16.5 ABI AC/CV mortality
Rajagopalan et al. 2006 [10]

























Cohen et al. 2010 [11] USA PC 512 61 55.9 6 19.8 NA 3.3 NA AC mortality
Adragao et al. 2012 [12] Portugal PC 219 65 60 36 6.8 20.0 41.0 ABI, vascular calcification AC/CV mortality
Otsubo et al. 2012 [13] Japan RC 86 59.8 69.8 105.6 15.1 19.8 22.1 ABI AC mortality
Thani et al. 2013 [14] Qatar PC 252 57 50.3 36 7.3 59.2 38.5 ABI, Clinical assessment AC mortality
Tsai et al. 2015 [15] Taiwan, China RC 444 61.6 46.4 79.2 7.7 32.7 24.8 ABI AC/CV mortality
Zhou et al. 2015 [16] China PC 116 56.4 53.4 72 7.1 9.5 18.0 ABI, clinical assessment,
history
AC/CV mortality
Abbreviations: PAD peripheral arterial disease; USA United states of America; PC prospective; RC retrospective; NA: not applicable; ABI ankle-brachial blood pressure index; AC: all-cause; CV cardiovascular. Multinationa:












Fig. 2 Association between PAD and risk of all-cause mortality in HD patients
Table 2 Assessment of study quality
References Quality indications form of Newcastle-Ottawa Scale Total
stars1 2 3 4 5A 5B 6 7 8
Fishbane et al. 1996 [8] ☆ ☆ ☆ ☆ ☆ ☆ ☆ - ☆ 8
Ono et al. 2003 [9] ☆ ☆ ☆ ☆ ☆ ☆ ☆ - ☆ 8
Rajagopalan et al.2006 [10]





















Cohen et al.2010 [11] ☆ ☆ - ☆ ☆ ☆ ☆ - ☆ 7
Adragao et al. 2012 [12] ☆ ☆ ☆ ☆ ☆ ☆ - - ☆ 7
Otsubo et al. 2012 [13] ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆ - 8
Thani et al. 2013 [14] ☆ ☆ ☆ ☆ ☆ ☆ - - - 6
Tsai et al. 2015 [15] ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆ 9
Zhou et al. 2015 [16] ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆ 9
For cohort studies: 1, exposed cohort truly or somewhat representative; 2, nonexposed cohort drawn from the same community as the exposed cohort; 3, ascertainment of
exposure; 4, outcome of interest not present at start; 5A, study controls for age; 5B, study controls for ≥ 3 additional risk factors; 6, assessment of outcome (independent blind
assessment or record linkage); 7, follow-up≥ 62 m; 8, complete accounting for cohorts or subjects lost to follow-up unlikely to introduce bias.
“☆”was scored 1 and “-” was scored “0”.
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The observed positive association was more pronounced
among prospective studies compared to retrospective
studies, and more pronounced among studies with
shorter follow-up time than studies with longer follow-up
time. Additionally, the association between PAD and
all-cause mortality significantly differed according to
the study design (P = 0.029 for the interaction) and
follow-up time (P = 0.029 for the interaction).
For CV mortality, we also conducted the subgroup meta-
analysis (Table 4). The possible confounding factors were
the same as that of all-cause mortality. All these subgroups
without statistical heterogeneity in all-cause mortality were
detected without statistical heterogeneity (all P values > 0.1)
either. Silmilarly, the observed positive association was
more pronounced among prospective studies compared to
retrospective studies, and more pronounced among studies
with shorter follow-up time than studies with longer
follow-up time. And the association between PAD and CV
mortality significantly differed according to the study
design (P = 0.048 for the interaction) and follow-up
time (P = 0.017 for the interaction). No heterogeneity
with each group stratified by duration of dialysis was
observed (both I2 = 0; P = 0.759 and 0.559, respectively),
however, the difference between the two pooled RRs
was not significant (P = 0.115).
Discussion
To our knowledge, this current study is the first meta-
analysis to synthesize the association between PAD and
risk of all-cause and CV mortality in HD patients. We
confirmed that PAD was independently associated with
a 115% higher adjusted RR for all-cause mortality on a
total of available 10 studies with 32,864 HD patients.
Moreover, for the CV mortality, a 199% higher risk was
yield on a total of 6 studies with 31,794 HD patients.
There was heterogeneity among the studies included.
Study design and follow up time were found to be two
potential sources of heterogeneity for all-cause and CV
mortality.
Fig. 3 Association between PAD and risk of CV mortality in HD patients
Yang et al. BMC Nephrology  (2016) 17:195 Page 6 of 9
The prevalence of PAD was higher in HD patients
than in general population. In our included 10 studies, the
highest prevalence of PAD was 41% and average prevalence
was 26.0%. The prevalence of PAD was 3%~ 10% in the
general population [22]. This may be explained by several
reasons: Firstly, it may be related to the old age in HD
patients. PAD mainly occurred after the age of 50 years old.
The prevalence rose with age [23]. It was 15%~ 20% in per-
sons > 70 years old [22] and by the age of 80, the prevalence
was around 20% [23]. Of note, the mean ages in our 10
studies ranged from 56.4 to 65 years old. So the prevalence
in our study may be higher than it in general population.
Secondly, in patients on maintenance HD, the immune dis-
orders and chronic inflammation were prevalent [24, 25].
They were mediated by inflammatory factors, such as β2-
Microglobulin, cystatin C and hsCRP and so on [26–32].
These factors acted on blood vessels persistently and
collectively to disorder the function of vascular endothelial
cell and to lead to atherogenesis eventually. And oxidative
stress injury and hypercoagulable states also played a role
in development of PAD [7]. Thirdly, some uremic toxins,
such as asymmetric dimethylarginine, could not be cleared
up by HD. These cumulative toxins would have a bad effect
on vascular endothelial cell and lead to atherogenesis [33].
Finally, renal failure can result in reduction of active vita-
min D in blood. The shortage of vitamin D played a part in
the progress of subclinical arteriosclerosis [34]. Of note, the
mechanism of PAD in HD patients is complex and need to
be explored in further pathophysiologic studies.
Our study demonstrated that PAD was associated with
increased mortality risk, which may be due to the
following reasons. Firstly, PAD is the narrow and ob-
structive lesions happened to aorta and limb blood supply
arteries usually secondary to atherosclerosis [7]. Ischemia
and necrosis were prevalent as a result of blockage of blood
supply to organs (except for the heart), limbs and torso.
Secondly, PAD was associated with other CV risk factors,
such as diabetes, dyslipidemia, hypertension, and smoking
[23, 35]. Thirdly, PAD led to a limitation in exercise per-
formance, which may cause the progression of athero-
sclerosis [36].
Fortunately, several treatments have shown beneficial
effects on the survival of patients with PAD. Firstly, anti-
platelet treatment had a 23% reduction of serious vascular
events for PAD patients, which was indicated by a meta
analysis of 42 randomized clinical trials including 9214
patients with PAD [37]. Secondly, the use of statin
drugs could reduce CV diseases fatality rate and all-
cause mortality [38, 39]. Thirdly, quitting smoking lead
to a lower 5-year mortality in patients with PAD [40].
However, there were no relevant clinical trials in HD
patients. There was only a pilot trial showed that pros-
taglandin I2 analog might improve symptoms of PAD in
HD patients, but did not report relevant mortality risk
Table 3 Subgroup meta-analysis for all-cause mortality
Subgroup No. of studies Pooled RR
(95 % CI)
I2 (%) Pa Pb
Study design
Prospective 6 2.67 (2.01, 3.55) 28.7 0.220 0.029
Retrospective 4 1.58 (1.28, 1.93) 28.1 0.243
Ascertainment of PAD with ABI only
Yes 4 2.33 (1.53, 3.53) 62.9 0.044 0.649
No 6 2.05 (1.48, 2.83) 64.1 0.016
Follow-up time, months
<62 6 2.72 (2.04, 3.64) 52.6 0.121 0.029
≥62 4 1.61 (1.30, 2.00) 37.1 0.189
Diabetes mullitus(%)
<29 5 2.13(1.58, 2.87) 18.2 0.299 0.940
≥29 4 2.25(1.38, 3.68) 84.2 0.000
PAD (%)
<26 6 1.92 (1.45, 2.55) 70.7 0.004 0.152
≥26 4 2.85 (1.98,4.10) 0 0.694
Duration of dialysis, years
<9.4 6 2.58 (1.97, 3.37) 28.9 0.218 0.124
≥9.4 2 1.72 (1.29, 2.31) 0 0.561
aP value for heterogeneity within each subgroup. bP value for heterogeneity
between subgroups in the meta-regression analysis
Table 4 Subgroup meta-analysis for CV mortality
Subgroup No. of
studies
RR (95 % CI) I2 (%) Pa Pb
Study design
Prospective 4 4.45 (2.43, 8.16) 42.9 0.154 0.048
Retrospective 2 1.45 (1.22, 1.73) 0 0.478
Ascertainment of PAD with ABI only
Yes 3 3.87 (1.55, 9.63) 68.5 0.042 0.493
No 3 2.33 (1.15, 4.72) 76.7 0.014
Follow-up time, months
<62 3 6.33 (3.54, 11.32) 0 0.953 0.017
≥62 3 1.65 (1.22, 2.24) 33.4 0.223
Diabetes mullitus(%)
<29 3 4.07 (1.81, 9.16) 44.4 0.166 0.389
≥29 3 2.36 (1.07, 5.22) 85.4 0.001
PAD (%)
<26 4 2.33 (1.30, 4.17) 80.7 0.001 0.160
≥26 2 7.13 (2.76, 18.4) 0 0.994
Duration of dialysis, years
<6.9 2 6.20 (3.29, 11.67) 0 0.795 0.115
≥6.9 2 2.14(1.37, 3.34) 0 0.559
aP value for heterogeneity within each subgroup. bP value for heterogeneity
between subgroups in the meta-regression analysis
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[41]. We are looking forward to high-quality random-
ized clinical trials in this area.
Diabetes mellitus may have an effect on the mortality risk
of PAD in HD patients. 7 included articles showed that
prevalence of diabetes mellitus was significantly higher in
HD patients with PAD than without PAD [9, 10, 13–17].
However, in our analysis, no difference of the observed
positive association was showed between the high and low
prevalence of diabetes mellitus in the HD populations.
Thani et al. revealed that PAD had a 2.45-fold increased
mortality in HD patients with diabetes and a 0.67-fold
increased mortality in HD patients without diabetes [42].
More similarly designed studies are needed to explore the
effect of diabetes mellitus in this topic.
PAD is diagnosed by an ABI value < 0.9 in either leg.
Besides, typical manifestations including intermittent
claudication and critical limb ischemia, and existence of
vascular obstruction based on ultrasonography or angiog-
raphy can also be used to diagnose PAD. ABI is calculated
by the ankle systolic pressure divided by the arm systolic
pressure. The two systolic pressures are measured simul-
taneously when the patients have a rest in a supine position
for 5 min. ABI measurement is simple, noninvasive and
cheap to be performed. Given the simple diagnosis and the
potential risk for mortality, PAD can be used as a con-
venient monitoring point for survival of HD patients.
Especially for those undergoing HD with hypertension,
diabetes, dyslipidemia, smoking, and age > 50 years,
screening for and management of PAD may achieve
higher cost-effectiveness.
The main strength of our study were all-inclusive avail-
able studies about theme of interest and the sufficient con-
sideration of potentially relevant confounding factors in
every article included. However, there were several potential
limitations as below. Firstly, subgroup analysis found that
for prospective studies (n = 6) there was a 167% increase
all-cause mortality, but for retrospective studies (n = 4) only
58% increase was shown. The difference was obvious and
statistically significant. Potentially, data for retrospective
studies were retrieved from existing records which may not
contain detailed clinical information. So as to assess the
association more precisely, we look forward to more mass
prospective studies. Secondly, existence of potential publi-
cation bias may lead to our exaggerating estimation of the
association between PAD and mortality risk. Finally, the
diagnosis criteria for PAD at baseline were not completely
uniform. For example, Rajagopalan et al. [10] diagnosed
PAD just by history and clinical assessment and left out
ABI measurement, which may result in lower positive
ratio of PAD patients compared with the other studies
using ABI. Meanwhile, ABI is now widely used to diag-
nose PAD, which may result in the early diagnosis of
PAD, therefore it might have some bias in our final
conclusion.
Conclusion
Our meta-analysis suggests PAD is associated with
increased risks of both all-cause and CV mortality in
patients on HD. For HD patients, this study may declare
the importance of PAD and bring out a risk factor for poor
prognosis. Additionally, the methods for PAD screening are
inexpensive, simple and noninvasive. PAD deserves to be
paid more attentions in HD patients. Since there was a
moderate to significant heterogeneity among studies and
confounding factors, more well-designed prospective stud-
ies and randomized clinical trials are needed in this area.
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